VOTRIENT® (pazopanib) – Important Change to Frequency of Serum Liver Test Monitoring for Hepatotoxicity

GlaxoSmithKline would like to inform healthcare professionals of an important safety update regarding a change in frequency of serum liver test monitoring for hepatotoxicity during use of VOTRIENT®. VOTRIENT® is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and for patients who have received prior cytokine therapy for advanced disease. Healthcare professionals are advised to monitor serum liver tests before initiating VOTRIENT® and at weeks 3, 5, 7, and 9. Thereafter, patients should be monitored at Month 3 and Month 4, and as clinically indicated. Periodic monitoring should continue after Month 4.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.